Sirona Biochem specializes in the development of carbohydrate-based molecules. While carbohydrate-based molecules offer immense commercial potential, we are focused on advancing three programs – therapeutics, cosmetic agents and biological ingredients.

Our most advanced program, a sodium glucose co-transporter (SGLT) for diabetes, achieved positive preclinical results. In a comparative study, Sirona Biochem’s SGLT inhibitor performed better than the leading drug candidate, Dapagliflozin (Bristol Myers Squibb & AstraZeneca) in this drug class.

Further preclinical studies of Sirona Biochem’s SGLT inhibitor to test for safety and toxicology are underway.   It is our intention to complete IND (Investigational New Drug)-enabling studies, then seek a pharmaceutical partner to handle the downstream clinical and commercial needs of our program.

While our cosmetic agents and biological ingredients do not require the same extensive clinical or preclinical testing as therapeutics, it is our plan to conduct several studies to demonstrate their effectiveness and safety before seeking cosmetic and laboratory partners for the commercial application of our products.